"With FSG's focus on Scandinavian companies at the cross-section of Technology and Life Science we are proud to invest in FidaBio and its unique first principle technology for biophysical analysis for the Pharma and Biotech industry. We look forward to work hard with the Fidabio team and EIFO as lead investors in this next phase of growth"
"As we close a year marked by more than double growth, we are pleased to complete a new round led by FSG, with continued support from EIFO and our other investors. With our amended team, we are confident that we are in the best possible position to continue supporting researchers in developing faster and better drugs - and to further accelerate the company's growth,"
Fida Biosystems, a Copenhagen-based life science tools company, secured €5 million from Danish EIFO and Swedish venture fund Fåhraeus Startup and Growth (FSG). FSG joins as a new investor while EIFO strengthens its commitment. The investment is an extension of a previous Series A and aims to prepare the company for a future Series B to support expansion and scaling. Fida's biophysical analysis platform enables faster, more accurate molecular and nanoparticle characterization to speed drug development. Over the past year, revenue doubled and more than 100 instruments were sold, showing rising adoption across industry and research.
Read at resund Startups
Unable to calculate read time
Collection
[
|
...
]